TOP2A and soft tissue sarcoma: Previous studies have reported that TOP2A constitutes a marker for predicting prognosis and response to various cancer therapies, for instance, breast cancer [223], soft tissue sarcomas [224], as well as clear cell renal cell carcinoma [225].